How Much Upside Is Left In Johnson & Johnson Stock?
For questions about this article or underlying research, email help@trefis.com.
Johnson & Johnson (JNJ) stock returned 53.9% over the past year, against 13.1% for the S&P 500. The shares now cost 42.0 times the company’s twelve-month earnings, against an average of 20.7 at the last 12 fiscal quarter ends. Those earnings include fiscal Q3 2026, when net income was $0.21 billion after talc and deal costs that management put at about $7 billion. If you own the shares after that run, or are thinking of buying, how much more could they make you over three years?
What Could Johnson & Johnson Stock Make You?
A three-year scenario based on the company’s own figures, rather than on a company forecast, finds that Johnson & Johnson stock would be worth 39.8% more, climbing 11.8% a year with dividends not counted. Here is the company today and three years on:
| Today | In three years (scenario) | |
|---|---|---|
| Revenue | $99.3 billion | $131 billion |
| Net margin | 16.2% | 20.2% |
| Earnings | $16.1 billion | $26.5 billion |
| P/E | 42.0 | 35.7 |
| Share price | $280.78 | $392.43 |
Most of that gain comes from selling more: the scenario grows revenue at 1.25 times the 7.8% pace of the twelve months to fiscal Q3 2026. Medicines bring in the bulk of the company’s sales: Innovative Medicine made 64.1% of fiscal 2025 revenue.
A wider net margin adds to the gain, as the scenario moves today’s margin three-tenths of the way back toward its average at the 12 earlier quarter ends. The scenario also assumes a year-three P/E 15% below today’s, because today’s is more than 1.15 times the stock’s own average. Even after that cut, the year-three P/E of 35.7 sits well above the 20.7 average, and a return to that average would turn the gain into a loss.
Johnson & Johnson Would Have To Grow Sales Faster
Johnson & Johnson has not grown revenue at the scenario’s pace in any of the last three twelve-month periods, which end a year apart. In fiscal Q3 2026, management said operational sales, which leave out currency moves, rose 7.9% in Innovative Medicine and 2.5% in MedTech, where the company fell short of its own expectations. Within the medicines business, oncology grew about 17% and Tremfya, an immunology drug, grew 68%.
Revenue growth has slowed since fiscal Q1 2026, reaching 5.9% from a year earlier in fiscal Q3. Management’s fiscal 2026 guide of about $101 billion says little about the pace ahead, since three of that year’s quarters are already reported. Further out, management said on the October 13, 2026 call that it sees a clear path to double-digit growth by the end of the decade, coming from its own investments rather than acquisitions.
How Johnson & Johnson’s Upside Changes Across Scenarios
Each row below changes one assumption and keeps the rest of the scenario as it is:
| If instead | Upside |
|---|---|
| Nothing changes (the scenario) | 39.8% |
| Revenue growth of 7.7% a year instead of 9.7% | 32.3% |
| Net margin of 29.4% in year three instead of 20.2% | 103.7% |
| P/E of 42.0 in year three instead of 35.7 | 64.4% |
| 5 years at the same assumptions instead of 3 | 68.3% |
Of the three assumptions, only the P/E is a drag on the gain, since the scenario sets it below today’s. The margin, by contrast, starts low: Johnson & Johnson’s net margin over the latest twelve months, 16.2%, is a little over half its average at the 12 earlier fiscal quarter ends. That average includes four quarter ends at 41.3% to 44.9%, and today’s figure takes in fiscal Q3 2026, the quarter hit by the talc and deal costs. In the three quarters before it, quarterly net margins ran at 20.8% to 21.9%, above the scenario’s 20.2%.
With the other assumptions held, the share price would be no higher in three years if revenue shrank 1.8% a year, against growth of 7.8% over the latest twelve months. The same would hold with a net margin of 14.4% in year three, against 16.2% today. So would a year-three P/E of 25.6, against 42.0 today.
Johnson & Johnson’s twelve-month net margin is the measure to watch in its next quarterly report, expected in January 2027. That figure will still include fiscal Q3 2026 and its talc and deal costs, so the new quarter’s own net margin will be the clearer guide to where margins stand.
What Would Selling Your Johnson & Johnson Shares Cost In Tax?
Shares from grants or a purchase plan, held for years, can carry a large taxable gain. A free 30-minute strategy review with our partner advisory firm covers a lower-tax way to sell them down and protect the rest.
Spot an error or want more like this? Tell us in 10 seconds.